Home > Healthcare > Pharmaceuticals > Pharma Manufacturing > Biological Safety Testing Market

Biological Safety Testing Market Trends

Report ID: GMI4278
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Biological Safety Testing Market Trends

Increased research and development (R&D) investments in clinical research and life sciences are instrumental in propelling the advancement of biological safety testing products and services. These investments ignite innovation within the field, empowering researchers to pursue exploratory projects aimed at uncovering and refining pioneering technologies and methodologies.

Increased R&D investments foster innovation and the development of advanced technologies for biological safety testing. This can lead to the creation of novel assays, improved testing methodologies, and enhanced instrumentation, allowing for more accurate, sensitive, and efficient testing of biological products.
R&D investments contribute to the improvement of quality control measures and the standardization of testing protocols in biological safety testing. This results in greater reliability and consistency of test results, reducing variability and ensuring the reproducibility of findings across different laboratories and testing facilities.
Thus, robust R&D efforts in clinical and life sciences research facilitate the expedited development and approval of new drugs, biologics, and medical devices. By streamlining the biological safety testing process and providing timely and reliable data on product safety, R&D investments contribute to faster regulatory approval and commercialization of innovative therapies and products, thereby stimulating market growth.

Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

Biological safety testing industry size was USD 4.1 billion in 2023 and will record a 13.6% CAGR between 2024 and 2032, attributed to the increasing focus on drug safety and quality control within the pharmaceutical and biotechnology industries.

The reagents and kits segment in the biological safety testing industry will reach USD 4.9 billion by 2032, owing to the pivotal role these components play in conducting a wide range of tests, from cell-based assays to endotoxin detection.

North America biological safety testing industry secured 1.7 billion in 2023, primarily due to the region's advanced healthcare infrastructure, stringent regulatory requirements, and significant investments in the biotechnology and pharmaceutical industries.

Major companies, including bioMérieux S.A., Charles River Laboratories International, Inc., Eurofins Scientific SE, F. Hoffmann-La Roche Ltd., Lonza Group Ltd., Merck KGaA, Samsung Biologics, Sartorius AG, SGS Societe Generale de Surveillance SA, and Thermo Fisher Scientific Inc., are operating in the market.